New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new ‘ophthalmology only’ pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Innovative products such as these have driven much of the […]